FRS Risk 與 TELLAPRIALBI 使用情況與統計

This multi-faceted application offers surgeons who perform pancreatoduodenectomy a comprehensive and versatile resource regarding pancreatic fistula, including the following features: 1. An easily accessible risk assessment tool with the ability to calculate the threat of developing a clinically-relevant pancreatic fistula in real-time. You can easily enter the four elements of the FRS and obtain an immediate, tailored appraisal of fistula risk, as well as other outcome metrics associated with fistulas. This can be calibrated along broader (FRS risk zones), to basic (FRS number), to very specific (distinct FRS scenarios) terms. 2. A guide to personalized medicine for pancreatic fistula where “best-practice” mitigation techniques are delineated for the specific situation you encounter in the operating room on any given day. This is backed up with detailed explanations and literature summaries regarding their applicability. 3. Your own individual practice data repository. This performance improvement aspect allows you to track updated data regarding your own fistula risk assumption, actual outcomes, and patterns of using various mitigation strategies available to you. In other words, this can form the basis of a performance-assessment strategy for your own personal practice. 4. A thorough, contemporary bibliography regarding pancreatic fistula literature, including the numerous studies done by the Pancreas Fistula Study Group that provide the scientific foundation for the knowledge offered. 5. Direct literature access with quick links to PubMed abstracts for all references. Additionally, free PDFs for select “key papers” are directly accessible. 6. Connection to an hour-long Cold Steel “Masterclass on Pancreatic Fistula” podcast, which provides a big-picture overview by synthesizing the many intriguing concepts influencing this dreaded complication.

Apple App Store
免費版
醫療

商店排名

- -

TELLAPRIALBI

The APRI and ALBI scores are commonly used in clinical routine to assess the severity of illness for patients suffering from hepatical tumors and to predict postoperative liver dysfunction after resection. Combining these scores, the APRI+ALBI score provides even better performance of assessment and prediction regarding 30-day-mortality after surgery. TELLAPRIALBI allows you to - enter relevant lab parameters (platelet count, AST, albumin and bilirubin levels) - automatically compute APRI, ALBI and APRI+ALBI scores for comparative review - select from a variety of tumor types together with the respective extent of resection and - view clinical interpretation plots regarding 30-day-mortality post operation highlighting the risk class indicated by the APRI+ALBI score. The app is intended for educational use by medical professionals and to allow review of the APRI+ALBI score and its predictive quality. All information entered into the app and computed by it is processed exclusively within the app on the users device and no information is stored, transmitted or shared by the app. TELLAPRIALBI was developed jointly by the Translational Experimental Liver Laboratory at the Medical University of Vienna (TELLVIENNA) and Howto Health GmbH. It is based on a joint research paper which is currently in print at BMJ Open. The app is published by and the service is provided by Howto Health GmbH.